FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature - Centre François Baclesse Accéder directement au contenu
Article Dans Une Revue European Journal of Nuclear Medicine and Molecular Imaging Année : 2019

FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature

Résumé

This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts' experience. Representative clinical cases are also discussed.
Fichier principal
Vignette du fichier
Aide2019_Article_FDGPETCTForAssessingTumourResp.pdf (4.44 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

inserm-02101049 , version 1 (26-11-2019)

Identifiants

Citer

Nicolas Aide, Rodney J Hicks, Christophe Le Tourneau, Stéphanie Lheureux, Stefano Fanti, et al.. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (1), pp.238-250. ⟨10.1007/s00259-018-4171-4⟩. ⟨inserm-02101049⟩
186 Consultations
193 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More